Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Drug development

New drug for diabetic kidney disease has promising results

In an international study, finerenone was effective at reducing protein in the urine without the rate of side effects of other drugs in the class.

Diabetic patients with high or very high albuminuria were randomly assigned to receive finerenone or placebo. Finerenone significantly reduced urinary albumin-creatinine ratio at day 90 versus placebo. In the image, histology of a human kidney

Source: Shutterstock.com

When a patient has kidney disease there can be high levels of protein in the urine, which could be treated with a new drug in development

Patients with chronic kidney disease usually have high levels of protein in their urine. This is effectively treated with a renin-angiotensin system blocker combined with a mineralocorticoid receptor antagonist. However, available therapies are underused because of an increased risk of high blood potassium levels (hyperkalemia).

But now a new option looks promising, based on positive results with a nonsteroidal mineralocorticoid receptor antagonist, finerenone (BAY94-8862). In an international study sponsored by Bayer, diabetic patients with high or very high albuminuria (n=823) taking an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker were randomly assigned to also receive finerenone or placebo.

As reported in JAMA (online, 1 September 2015)[1], finerenone reduced urinary albumin-creatinine ratio at day 90 versus placebo and hyperkalemia only occurred in 0–3.2% of finerenone-treated patients. A longer-term study will be carried out to investigate clinical endpoints.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20069299

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Drugs of Abuse

    Drugs of Abuse

    A concise, easy-to-read guide for healthcare professionals who encounter drug abuse.

    £38.00Buy now
  • Pharmaceutical Toxicology

    Pharmaceutical Toxicology

    Explains the methodology and requirements of pre-clinical safety assessments of new medicines. Includes registration requirements and pharmacovigilance.

    £40.00Buy now
  • Adverse Drug Reactions

    Adverse Drug Reactions

    A practical guide to the drug reactions that affect particular organ systems, and the management of these reactions.

    £38.00Buy now
  • English Delftware Drug Jars

    English Delftware Drug Jars

    This beautiful book illustrates the art and history of the collection of English delftware drug jars in the Museum of the Royal Pharmaceutical Society of Great Britain.

    £54.00Buy now
  • Paediatric Drug Handling

    Paediatric Drug Handling

    Written for new pharmaceutical scientists, this book provides a background in paediatric pharmacy and a comprehensive introduction to children's medication.

    £33.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Diabetic patients with high or very high albuminuria were randomly assigned to receive finerenone or placebo. Finerenone significantly reduced urinary albumin-creatinine ratio at day 90 versus placebo. In the image, histology of a human kidney

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.